Improving Treatment for IPF

Trial Objective

Improving Treatment for IPFResearchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available. 

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

Adults 40 years of age and older.

Age: 40+    Gender: Any Gender


Estimated Time Commitment

8 visits to the study center, plus phone visits to review lab results

Visits will take two to four hours.



Payment & Reimbursement  

Payment: Not Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Kaitlin Fier

Kaitlin Fier
303.270.2852

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health

Principal Investigators

Co-Investigators


Request More Information

Complete this form to learn more about this study and see if you qualify.


*
*
*
*